Patient Enrollment Concluded Early in PEGASUS Phase 3 Pemphigus Trial for Rilzabrutinib
24 nov. 2020 08h00 HE
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc., a Sanofi company, focused on developing treatments for immune mediated diseases, today announced it has...
Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease
17 sept. 2020 08h01 HE
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated...
Principia Biopharma Reports Second Quarter 2020 Financial Results
06 août 2020 16h05 HE
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated...
Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis
23 juin 2020 01h15 HE
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated...
Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus
12 juin 2020 16h05 HE
|
Principia Biopharma Inc.
Clear dose-response combined with decreased daily corticosteroid usage Response rate increased with extended duration of treatment to six months while maintaining a favorable safety profile ...
Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
12 juin 2020 06h05 HE
|
Principia Biopharma Inc.
Oral BTK inhibitor reaches primary endpoint in 50 percent of patients treated > 12 weeks; demonstrates fast onset and durable responses Principia to initiate pivotal Phase 3 trial in ITP ...
Principia Biopharma to Hold Virtual Analyst Event to Discuss BTK Inhibition: Beyond B Cells and Antibodies
03 juin 2020 16h01 HE
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated...
Principia Announces Data Presentations of Rilzabrutinib in Patients with Immune Thrombocytopenia (ITP) at Two Upcoming Virtual Medical Meetings
26 mai 2020 08h01 HE
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated...
Principia Announces AAD Late Breaker Research Presentation of its Pemphigus Phase 2 Part B Trial
12 mai 2020 08h05 HE
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated...
Principia Biopharma Reports First Quarter 2020 Financial Results
06 mai 2020 16h05 HE
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated...